推荐产品
表单
powder
质量水平
创始人
Abbott
储存温度
2-8°C
SMILES字符串
Cl[H].CCCNCC(O)COc1ccccc1C(=O)CCc2ccccc2
InChI
1S/C21H27NO3.ClH/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17;/h3-11,18,22-23H,2,12-16H2,1H3;1H
InChI key
XWIHRGFIPXWGEF-UHFFFAOYSA-N
基因信息
human ... ABCB1(5243) , ADRB1(153) , ADRB2(154) , ADRB3(155) , CYP1A2(1544) , SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)
正在寻找类似产品? 访问 产品对比指南
一般描述
Propafenone hydrochloride is a calcium antagonist. It functions as a Na+ and K+ channel blocker. It might be used to treat patients with systemic hypertension. Propafenone hydrochloride is associated with bradycardia and bronchospasms. It is metabolized in the liver. Propafenone hydrochloride is used to treat ventricular arrhythmias.
应用
Propafenone hydrochloride has been used in the isolation of cardiomyocytes.
生化/生理作用
Blocks hKv1.5 and ATP-sensitive K+ channels; class 1C antiarrhythmic agent that is also an antagonist at β adrenergic receptors.
特点和优势
This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 3
法规信息
新产品
A Seki et al.
British journal of pharmacology, 126(5), 1153-1162 (1999-04-16)
1. The class Ic anti-arrhythmic agent, flecainide is known to inhibit the transient outward K current (Ito) selectively in human atrium. We studied the effects of propafenone, another class Ic antiarrhythmic agent, on K currents in human atrial myocytes using
Lori D Bash et al.
Cardiovascular drugs and therapy, 26(2), 167-179 (2012-03-16)
Rate and rhythm control are two well established treatment objectives for atrial fibrillation (AF) patients. While symptom reduction is a primary treatment goal, therapeutic practice related to cardioversion varies by region and patient, with several precautions associated with the use
The multiple modes of action of propafenone
Dukes ID and Williams EMV
European Heart Journal, 5(2), 115-125 (1984)
Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study
Opolski G, et al.
Chest, 126(2), 476-486 (2004)
Pharmacologic management of arrhythmias
Ganjehei L, et al.
Texas Heart Institute Journal, 38(4), 344-344 (2011)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门